Cerenome completes enrollment in Phase 2 ReSPECT-GBM radiotherapy trial
Cerenome (Nasdaq: CNSY) has completed enrollment in the Phase 2 portion of its ReSPECT-GBM trial, evaluating REYOBIQ (rhenium Re186 obisbemeda) in adults with recurrent glioblastoma. The Houston-based CNS oncology company treated 32 patients at the recommended Phase 2 dose, one fewer than the planned 34, after a statistical review concluded the cohort was sufficient to support the final analysis with minimal impact on statistical power. Topline data are expected in mid-2027, after which the company intends to hold an End-of-Phase 2 meeting with the FDA to map out next steps for the programme.
REYOBIQ is an investigational nanoliposomal radiotherapeutic that delivers beta radiation from the radioisotope rhenium-186 directly into CNS tumours via convection-enhanced delivery catheters inserted into the tumour. Because the drug bypasses the blood-brain barrier entirely, the approach is designed to concentrate a high absorbed dose at the tumour site while limiting systemic and healthy-tissue exposure. Rhenium-186 also emits gamma radiation, enabling real-time imaging of drug distribution.
What the data show so far
Previously reported results from the Phase 1 study, published in Nature Communications in 2025, showed that patients whose tumours received an absorbed dose of 100 Gy or more had a median overall survival of 17 months (95% CI 8.0 to 35.0), compared with six months in patients who received sub-therapeutic doses. A dose-response relationship was also observed: each additional 100 Gy of absorbed dose was associated with a 35.7% lower risk of death (HR 0.643; p=0.003).
Interim Phase 2 data, presented at the Society for Neuro-Oncology Annual Meeting in November 2023, showed a median overall survival of 13 months in the first 15 patients treated, against a historical comparator of approximately eight months for bevacizumab monotherapy. Median progression-free survival was 11 months, against roughly four months for standard of care. The company noted that 88.9% of Phase 2 patients evaluated at that point met the key convection-enhanced delivery targets associated with longer survival in Phase 1. Safety data across Phase 1 and Phase 2 showed most adverse events were Grade 1 or 2, with no treatment-related deaths and no discontinuations due to serious adverse reactions.
Lead investigator Andrew Brenner, Professor of Medicine at the Mays Cancer Center at UT Health San Antonio, noted that the Phase 1 finding of 17-month median survival in high-dose patients established a clear delivery goal for Phase 2. "Getting REYOBIQ to the tumor at therapeutic doses has been the focus of this trial," he said, "and the final Phase 2 data will show how well that approach holds up in a larger group of patients."
Market context and competitive landscape
Recurrent glioblastoma remains one of oncology's most intractable indications. No therapy has been approved in the recurrent setting since bevacizumab received accelerated approval from the FDA in 2009, and that approval has not translated into an overall survival benefit in confirmatory trials. The paucity of effective options means regulators have shown willingness to engage constructively with novel delivery modalities, including local and locoregional approaches that sidestep the blood-brain barrier problem that has confounded systemic therapies.
Several companies are pursuing intratumoural and locoregional strategies in GBM, including viral-vector based gene therapies and oncolytic virus platforms. REYOBIQ's radiotherapeutic mechanism and its ability to image drug distribution in real time represent a distinct approach. The interim survival signal, if it holds in the full 32-patient cohort, would be clinically meaningful against a backdrop where median overall survival in recurrent GBM has not materially improved in over a decade.
Cerenome also runs parallel REYOBIQ trials in leptomeningeal metastases and paediatric brain cancers, and operates a cerebrospinal-fluid diagnostics platform, CNSide. The combination positions the company as a vertically integrated CNS oncology operator, though the commercial and regulatory paths for each programme remain at early stages. The mid-2027 topline readout will be the most significant catalyst the company has yet faced.